Company Filing History:
5 out of 3,923 
5 out of 2,596 
Years Active: 2017-2023
Title: The Innovative Contributions of Saad Kenderian
Introduction
Saad Kenderian is a prominent inventor based in Philadelphia, PA, known for his significant contributions to the field of cancer treatment. With a total of five patents to his name, Kenderian has made remarkable strides in developing innovative therapies that target specific cancer markers.
Latest Patents
One of Kenderian's latest patents focuses on the treatment of cancer using a CD123 chimeric antigen receptor. This invention provides compositions and methods for treating diseases associated with the expression of CD123. It also relates to a chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. Furthermore, the invention includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
Career Highlights
Throughout his career, Kenderian has worked with notable organizations such as Novartis AG and the University of Pennsylvania. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in cancer therapies.
Collaborations
Some of Kenderian's notable coworkers include Jennifer Brogdon and Saar Gill. Their collaborative efforts have further advanced the research and development of innovative cancer treatments.
Conclusion
Saad Kenderian's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. His patents and collaborations highlight his commitment to advancing healthcare through scientific research and development.